Table 4 Toxicity
From: Bendamustine in patients with relapsed or refractory multiple myeloma
| Â | Â | Â | Subgroups therapy mode | Subgroups dosage | ||||
|---|---|---|---|---|---|---|---|---|
Toxicity | Â | All | Monotherapy | + Steroids | p | 80-100 mg/m 2 | 100-120 mg/m 2 | p |
| Â | Â | n = 39 | n = 12 | n = 27 | Â | n = 21 | n = 18 | Â |
Anaemia | ° I-II | 32 (82%) | 10 (84%) | 22 (81%) | 1,0 | 17 (81%) | 15 (83%) | 1,0 |
|  | ° III-IV | 4 (10%) | 1 (8%) | 3 (11%) | 1,0 | 3 (14%) | 1 (6%) | 0,6 |
|  | ° I-IV | 36 (92%) | 11 (92%) | 25 (92%) | 1,0 | 20 (95%) | 16 (89%) | 0,6 |
Neutropenia | ° I-II | 19 (49%) | 5 (42%) | 14 (52%) | 0,7 | 8 (38%) | 11 (61%) | 0,2 |
|  | ° III-IV | 16 (41%) | 6 (50%) | 10 (37%) | 0,5 | 11 (52%) | 5 (28%) | 0,2 |
|  | ° I-IV | 35 (90%) | 11 (92%) | 24 (89%) | 1,0 | 19 (90%) | 16 (89%) | 1 |
Thrombopenia | ° I-II | 18 (46%) | 4 (33%) | 14 (52%) | 0,3 | 9 (43%) | 9 (50%) | 0,7 |
|  | ° III-IV | 10 (26%) | 4 (33%) | 6 (22%) | 0,7 | 8 (38%) | 2 (11%) | 0,7 |
|  | ° I-IV | 28 (72%) | 8 (66%) | 20 (74%) | 0,7 | 17 (81%) | 11 (61%) | 0,3 |
Infection | ° I-II | 3 (8%) | 0 (0%) | 3 (11%) | 0,5 | 2 (10%) | 1 (6%) | 1,0 |
|  | ° III-IV | 6 (15%) | 0 (0%) | 6 (22%) | 0,2 | 3 (14%) | 3 (11%) | 1,0 |
|  | ° I-IV | 9 (23%) | 0 (0%) | 9 (33%) | 0,04 | 5 (24%) | 4 (17%) | 1,0 |
Other Side Effects | ° I-II | 12 (31%) | 3 (25%) | 9 (33%) | 0,7 | 10 (48%) | 2 (11%) | 0,02 |
|  | ° III-IV | 1 (3%) | 0 (0%) | 1 (4%) | 1,0 | 0 (0%) | 1 (6%) | 0,5 |
|  | ° I-IV | 13 (33%) | 3 (25%) | 10 (37%) | 0,7 | 10 (48%) | 3 (17%) | 0,05 |